Overview

A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Status:
Not yet recruiting

Trial end date:
2028-11-30

Target enrollment:

Participant gender:

Summary

This is a single-arm, phase II trial evaluating the efficacy and safety of SHR-A1811 combined with pyrotinib maleate in Stage II-III HER2-positive breast cancer. Subjects will receive the neoadjuvant therapy of SHR-A1811 and pyrotinib for six cycles, and then undergo surgery within 4 weeks after neoadjuvant therapy. Efficacy will be assessed every 2 cycles.

Phase:

Phase 2

Details

Lead Sponsor:

Shengjing Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.